The cytosine deaminase APOBEC3B affects responses to therapy in estrogen receptor positive breast cancer cells

被引：0
|
作者：
LaPara, Kelly S.
Law, Emily
Harris, Reuben
Yee, Douglas
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-295
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
295
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Discovery of APOBEC3B DNA cytosine deaminase ligands by protein observed fluorine NMR screening
    Grillo, Michael
    Pomerantz, William
    Aihara, Hideki
    Harki, Daniel
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
  • [22] Degradation of the cancer genomic DNA deaminase APOBEC3B by SIV Vif
    Land, Allison M.
    Wang, Jiayi
    Law, Emily K.
    Aberle, Ryan
    Kirmaier, Andrea
    Krupp, Annabel
    Johnson, Welkin E.
    Harris, Reuben S.
    ONCOTARGET, 2015, 6 (37) : 39969 - 39979
  • [23] APOBEC3B is an enzymatic source of mutation in breast cancer
    Michael B. Burns
    Lela Lackey
    Michael A. Carpenter
    Anurag Rathore
    Allison M. Land
    Brandon Leonard
    Eric W. Refsland
    Delshanee Kotandeniya
    Natalia Tretyakova
    Jason B. Nikas
    Douglas Yee
    Nuri A. Temiz
    Duncan E. Donohue
    Rebecca M. McDougle
    William L. Brown
    Emily K. Law
    Reuben S. Harris
    Nature, 2013, 494 : 366 - 370
  • [24] ILF2 enhances the DNA cytosine deaminase activity of tumor mutator APOBEC3B in multiple myeloma cells
    Yasuhiro Kazuma
    Kotaro Shirakawa
    Yusuke Tashiro
    Hiroyuki Yamazaki
    Ryosuke Nomura
    Yoshihito Horisawa
    Suguru Takeuchi
    Emani Stanford
    Yoshinobu Konishi
    Hiroyuki Matsui
    Tadahiko Matsumoto
    Fumiko Tanabe
    Ryo Morishita
    Shinji Ito
    Akifumi Takaori-Kondo
    Scientific Reports, 12
  • [25] ILF2 enhances the DNA cytosine deaminase activity of tumor mutator APOBEC3B in multiple myeloma cells
    Kazuma, Yasuhiro
    Shirakawa, Kotaro
    Tashiro, Yusuke
    Yamazaki, Hiroyuki
    Nomura, Ryosuke
    Horisawa, Yoshihito
    Takeuchi, Suguru
    Stanford, Emani
    Konishi, Yoshinobu
    Matsui, Hiroyuki
    Matsumoto, Tadahiko
    Tanabe, Fumiko
    Morishita, Ryo
    Ito, Shinji
    Takaori-Kondo, Akifumi
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [26] APOBEC3B is an enzymatic source of mutation in breast cancer
    Burns, Michael B.
    Lackey, Lela
    Carpenter, Michael A.
    Rathore, Anurag
    Land, Allison M.
    Leonard, Brandon
    Refsland, Eric W.
    Kotandeniya, Delshanee
    Tretyakova, Natalia
    Nikas, Jason B.
    Yee, Douglas
    Temiz, Nuri I. A.
    Donohue, Duncan E.
    McDougle, Rebecca M.
    Brown, William L.
    Law, Emily K.
    Harris, Reuben S.
    NATURE, 2013, 494 (7437) : 366 - 370
  • [27] The deaminase APOBEC3B triggers the death of cells lacking uracil DNA glycosylase
    Serebrenik, Artur A.
    Starrett, Gabriel J.
    Leenen, Sterre
    Jarvis, Matthew C.
    Shaban, Nadine M.
    Salamango, Daniel J.
    Nilsen, Hilde
    Brown, William L.
    Harris, Reuben S.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (44) : 22158 - 22163
  • [28] Apobec mutation signature in breast cancer explained by combinatorial action of apobec3a and apobec3b
    Harris, Reuben S.
    Jarvis, Matthew C.
    Carpenter, Michael A.
    Brown, Margaret R.
    Argyris, Prokopios P.
    Brown, William
    Yee, Douglas
    CANCER RESEARCH, 2022, 82 (04)
  • [29] APOBEC3B expression and its prognostic potential in breast cancer
    Mao, Yan
    Lv, Meng
    Zhang, Yuzi
    Nie, Gang
    Cui, Jian
    Wang, Yongmei
    Wang, Yuanyuan
    Cao, Weihong
    Liu, Xiaoyi
    Wang, Xingang
    Wang, Haibo
    ONCOLOGY LETTERS, 2020, 19 (04) : 3205 - 3214
  • [30] DNA deaminase APOBEC3B regulates theresponse to PARP inhibitors of epithelial ovarian cancer stem cells
    Isquith, Jane
    Pham, Jessica
    Phavong, Robert
    Rivera, Maria
    Fisch, Kathleen
    Jamieson, Catriona
    McHale, Michael
    Eskander, Ramez
    Jiang, Qingfei
    CANCER RESEARCH, 2022, 82 (12)
12345